Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Chimera Antigen Receptor (CAR)”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT04083495
What this trial is testing

CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma

Who this might be right for
Peripheral T Cell Lymphoma
UNC Lineberger Comprehensive Cancer Center 20
Large-scale testing (Phase 3)Looking for participantsNCT07391657
What this trial is testing

A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)

Who this might be right for
Relapsed Refractory Multiple Myeloma
AstraZeneca 508
Early research (Phase 1)Active Not RecruitingNCT05753501
What this trial is testing

Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies

Who this might be right for
Hematologic Cancer
AbbVie 135
Very early researchUnknownNCT04173988
What this trial is testing

Study of alloCART-19 Cell Therapy in Pediatric Patients With Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

Who this might be right for
ALL, Childhood B-Cell
Children's Hospital of Fudan University 6
Testing effectiveness (Phase 2)Active Not RecruitingNCT06868290
What this trial is testing

Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Severe Active GPA or MPA

Who this might be right for
ANCA Associated Vasculitis (AAV)
Novartis Pharmaceuticals 126
Testing effectiveness (Phase 2)UnknownNCT02944162
What this trial is testing

CAR-pNK Cell Immunotherapy for Relapsed/Refractory CD33+ AML

Who this might be right for
Acute Myelogenous LeukemiaAcute Myeloid LeukemiaAcute Myeloid Leukemia With Maturation+2 more
PersonGen BioTherapeutics (Suzhou) Co., Ltd. 10
Early research (Phase 1)Active Not RecruitingNCT07809594
What this trial is testing

CS1-Targeted CAR-T Cells for Relapsed/Refractory Multiple Myeloma

Who this might be right for
Relapsed/Refractory Multiple Myeloma (RRMM)Plasma Cell Myeloma
Institute of Hematology & Blood Diseases Hospital, China 10
Early research (Phase 1)Active Not RecruitingNCT03085173
What this trial is testing

A Trial of "Armored" CAR T Cells Targeting CD19 For Patients With Relapsed CD19+ Hematologic Malignancies

Who this might be right for
Chronic Lymphocytic Leukemia (CLL)RelapsedRefractory
Memorial Sloan Kettering Cancer Center 39
Testing effectiveness (Phase 2)UnknownNCT04272151
What this trial is testing

Safety and Efficacy of BCMA-Targeted CAR-T Therapy for Relapsed/Refractory Multiple Myeloma

Who this might be right for
Multiple MyelomaMultiple Myeloma in RelapseNeoplasm, Plasma Cell
Chongqing Precision Biotech Co., Ltd 40
Early research (Phase 1)Study completedNCT04488354
What this trial is testing

Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T

Who this might be right for
Relapsed/Refractory B-cell LymphomasDiffuse Large B-Cell Lymphoma (DLBCL)Follicular Lymphoma (FL)+9 more
Calibr, a division of Scripps Research 16
Early research (Phase 1)UnknownNCT05640713
What this trial is testing

Assessment of Safety and Efficacy of ThisCART19A in Adult Patients With B Cell Malignancies After Failure of Autologous Chimeric Antigen Receptor T- Cell(CAR-T) Therapy

Who this might be right for
Allogeneic, CAR-T, Protein Sequestration, Non-gene Edited
Henan Cancer Hospital 12
Not applicableUnknownNCT03327285
What this trial is testing

C-CAR011 Treatment in Subjects With ALL After HSCT

Who this might be right for
Acute Lymphoblastic Leukemia(ALL)
Peking University People's Hospital 40
Early research (Phase 1)Study completedNCT05149391
What this trial is testing

C-CAR039 in Subjects With Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma

Who this might be right for
B Cell Non-Hodgkin's Lymphoma
Peking University 3
Early research (Phase 1)WithdrawnNCT01316146
What this trial is testing

Administration of T Lymphocytes for Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma (CART CD30)

Who this might be right for
Non-Hodgkin's LymphomaHodgkin's Lymphoma
UNC Lineberger Comprehensive Cancer Center
Early research (Phase 1)UnknownNCT03114670
What this trial is testing

Donor-derived Anti-CD123-CART Cells for Recurred AML After Allo-HSCT

Who this might be right for
Adult Acute Myeloid Leukemia
Affiliated Hospital to Academy of Military Medical Sciences 20
Testing effectiveness (Phase 2)WithdrawnNCT02547961
What this trial is testing

Chimeric Antigen Receptor-Modified T Cells for Breast Cancer

Who this might be right for
Breast Cancer
Fuda Cancer Hospital, Guangzhou
Early research (Phase 1)Looking for participantsNCT03721068
What this trial is testing

Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma

Who this might be right for
NeuroblastomaOsteosarcoma
UNC Lineberger Comprehensive Cancer Center 18
Testing effectiveness (Phase 2)Active Not RecruitingNCT06038474
What this trial is testing

Descartes-08 for Patients With Systemic Lupus Erythematosus

Who this might be right for
Systemic Lupus Erythematosus (SLE)
Cartesian Therapeutics 6
Testing effectiveness (Phase 2)Ended earlyNCT06400303
What this trial is testing

KYSA-5: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Systemic Sclerosis

Who this might be right for
Systemic SclerosisSystemic Sclerosis - Diffuse CutaneousSystemic Sclerosis - 2013 ACR/EULAR Classification Criteria
Kyverna Therapeutics 3
Testing effectiveness (Phase 2)Ended earlyNCT06342960
What this trial is testing

KYSA-3: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis

Who this might be right for
Lupus NephritisLupus Nephritis - WHO Class IIILupus Nephritis - WHO Class IV
Kyverna Therapeutics 2
Next Page